tbuckley/cabot-search huggingface dataset:
Transplant Outcomes and Stabilization of Neurological Function in Young Children with MPS III (Sanfilippo Syndrome) after Unrelated Donor Umbilical Cord Blood Transplantation.
Authors: Sonali Lakshminarayanan, Paul Szabolcs, Vinod K. Prasad, Suhag Parikh, June Allison, Susan J. Wood, Maria Escolar, Joanne Kurtzberg
Journal: Blood (2005)
Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor.
Authors: Marcelo C. Pasquini, Marian Ewell, Edward A. Stadtmauer, Christopher N. Bredeson, Edwin P. Alyea, Keith Stockerl-Goldstein, Amrita Krishnan, Firoozeh Sahebi, Scott D. Rowley, David G. Maloney, David H. Vesole, Mary M. Horowitz, Shelly Carter, Nancy Geller, Sergio Giralt
Journal: Blood (2007)
PPARγ Regulates the Anti-Inflammatory Effects of Carbon Monoxide on Macrophages: A Gene Profiling Study.
Authors: Martin Bilban, Sherrie L. Otterbein, Emeka Ifedigbo, Keiji Enjyoji, Anny Usheva, Simon C. Robson, Fritz H. Bach, Leo E. Otterbein, Oswald Wagner
Journal: Blood (2004)
Impaired GvL Potential of Natural Killer Cells Early Reconstituting Following Haploidentical HSCT.
Authors: Luca Vago, Elisabetta Zino, Simona Di Terlizzi, Barbara Forno, Maria T. Lupo Stanghellini, Serena K. Perna, Benedetta Mazzi, Jacopo Peccatori, Silvano Rossini, Maria G. Roncarolo, Chiara Bonini, Fabio Ciceri, Claudio Bordignon, Katharina Fleischhauer
Journal: Blood (2006)
Unfavorable Prognostic Value of IKAROS but Not CRLF2 in Children with BCRABL1-positive Acute Lymphoblastic Leukemia,
Authors: Arian Van Der Veer, Marieke E. Willemse, Valerie De Haas, Anjo J.P. Veerman, Willem A. Kamps, Rob Pieters, Monique L. Den Boer
Journal: Blood (2011)
Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) after T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (haplo-HSCT)
Authors: Neena Kapoor, Alice Bertaina, Pietro Merli, Swati Naik, Waseem Qasim, Mary Slatter, Reem Elfeky, Barbarella Lucarelli, Monika Smogorzewska, Giuseppina Li Pira, Valentina Bertaina, Annemarie Moseley, Franco Locatelli
Journal: Blood (2016)
Microenvironment-Induced Expression of PIM Kinases Supports Chronic Lymphocytic Leukemia Cells Survival and Promotes CXCR4-mTOR Pathway Dependent Migration
Authors: Emilia Bialopiotrowicz, Patryk Gorniak, Bartosz Pula, Monika Noyszewska-Kania, Hanna Makuch-Lasica, Grazyna Nowak, Maciej Szydlowski, Ewa Jablonska, Tomasz Sewastianik, Anna Polak, Ewa Lech-Maranda, Bozena Katarzyna Budziszewska, Maja Wasylecka, Katarzyna Borg, Krzysztof Warzocha, Wojciech Czardybon, Michal Galezowski, Renata Windak, Krzysztof Brzozka, Przemyslaw Juszczynski
Journal: Blood (2016)
Correction of Anemia in the Frail Elderly (CAFÉ): Results of a Randomized, Double-Blind, Placebo-Controlled Study with Darbepoetin Alfa in Elderly Patients with Chronic Unexplained Anemia
Authors: Arturo Loaiza-Bonilla, Andrew Artz, Francis Salerno, Sean X Leng, Shing-Shing Yeh, Rex Biedenbender, Stefan Gravenstein, Jose Loera, Zeba Shaheen Geloo, William B Ershler
Journal: Blood (2012)
Temporal, Quantitative and Functional Characteristics of Single-KIR Positive Alloreactive NK Cell Recovery Account for Impaired Graft Versus Leukemia Activity after Haploidentical HSCT.
Authors: Luca Vago, Barbara Forno, Elisabetta Zino, Simona Di Terlizzi, Maria T. Lupo Stanghellini, Roberto Crocchiolo, Serena K. Perna, Attilio Bondanza, Benedetta Mazzi, Jacopo Peccatori, Maria G. Roncarolo, Claudio Bordignon, Chiara Bonini, Fabio Ciceri, Katharina Fleischhauer
Journal: Blood (2007)
MYD88 (L265P) Mutation Confers Very Poor Response and Outcome after Second-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Antonio Salar, Francesc Garcia-Pallarols, Concepcion Fernández-Rodríguez, Blanca Sánchez-González, Mari Carmen Vela, Eva Gimeno, Silvia Pairet, Alicia Senin, Laura Camacho, Sergi Serrano, Carlos Besses, Beatriz Bellosillo
Journal: Blood (2014)
Results From The Korean Imatinib Discontinuation Study (KIDS): Updated Data With 14-Month Median Follow Up
Authors: Yun jeong Oh, Soo Young Choi, Sung-Eun Lee, Soo-Hyun Kim, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Joon Seong Park, Seong Hyun Jeong, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Dong Hoe Koo, Hawk Kim, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny Park, Ho-Jin Shin, DongWook Kim
Journal: Blood (2013)
Response to ‘Titre-specific positive predictive value of anti-nuclear antibody patterns’ by Vulsteke <i>et al</i>
Authors: Jan Damoiseaux, Luís Eduardo Coelho Andrade, Marvin J Fritzler, Manfred Herold, Maria Infantino, Carlos von Muhlen
Journal: Annals of the Rheumatic Diseases (2019)

Correspondence responsedoes not necessarily hold for the values calculated in the patient cohort from Belgium.Here, we argue that the PPV can even be further increased, as well as the NPV in case of the nuclear dense fine speckled pattern (AC-2), by considering the full ICAP HEp-2 IIFA pattern classification.Eventually, we fully agree with the statement that confirmatory antigen-specific immunoassays are mandatory in all cases, preferentially by taking into account the diagnostic suspicion at the time of presentation, the centromere pattern (AC-3) being the only possible exception.
Germinal Center-Derived Lymphomas and Plasmacytomas in Mice with Targeted Deletion of MiR-15a/16-1 in Activated B Cells
Authors: Tomasz Sewastianik, Jianjun Zhao, Meng Jiang, Jianli Wang, Vinodh Pillai, Peter S. Dennis, Jianhong Lin, Daniel Brooks, Mary Bouxsein, Geraldine S Pinkus, Petr Jarolim, Davide Robbiani, Irene M. Ghobrial, Kenneth C. Anderson, Ruben D. Carrasco
Journal: Blood (2016)
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study
Authors: Erin L. Schenk, Sumithra J. Mandrekar, Grace K. Dy, Marie Christine Aubry, Angelina D. Tan, Shaker R. Dakhil, Bradley A. Sachs, Jorge J. Nieva, Erin Bertino, Christine Lee Hann, Steven E. Schild, Troy W. Wadsworth, Alex A. Adjei, Julian R. Molina
Journal: Journal of Thoracic Oncology (2019)
Identifying novel molecular differences between WHO grade I and II meningiomas
Authors: Agbolahan (Boh) Sofela, Oliver Hanemann
Journal: Neuro-Oncology (2019)

Abstract Background With the increasing emphases on the integrated histo-pheno-genotypical diagnoses of central nervous system (CNS) tumours, there is a pressing need for the identification of biomarkers to aid in the clinical management, diagnosis, prognosis and follow-up of meningiomas too. WHO grade II meningiomas remain a very controversial group of CNS tumours to diagnose/treat, compared to the more prevalent and extensively researched grade I tumours. Typical clinical scenarios include; the serum diagnosis of conservatively managed tumours, follow-up of surgically managed patients and prognostication, for predicting grade progression. We herein describe the identification of novel biomolecular differences between grade I and II meningiomas. Aim To identify biomarkers unique to grade II meningiomas (versus grade I) and describe their potential use in typical clinical scenarios. Methods Unbiased global proteomic analyses of four grade I &amp; II primary-meningioma cells were carried out to identify proteins differentially expressed between both grades. Differential expression and statistical analyses were performed using Perseus and Microsoft Excel. The significantly differentially expressed proteins were validated by Western blot, IHC and ELISA, using tumour tissue and primary cells. Results We identified 3553 proteins commonly expressed in both meningioma grades. Further analysis revealed that 86 of these were significantly differentially up/down-regulated. Initial validation studies on some of the most promising candidates have confirmed these patterns of expressions between the two tumour grades. Conclusion There is a need for the identification of grade II biomarkers. The initial findings of this study have identified novel biomolecular differences between grade I/II meningiomas that can potentially aid in the aforementioned typical clinical scenarios.
Plasma Membrane Loss in Maturing Human Reticulocytes Occurs Through Endocytosis of Large Glycophorin A- Containing Vacuoles Which Fuse with Autophagosomes Before Exocytosis
Authors: Rebecca E Griffiths, Sabine Kupzig, Nicola Cogan, Virginie Betin, Tosti J Mankelow, Jon Lane, Steve F Parsons, David J. Anstee
Journal: Blood (2011)
Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia.
Authors: Rachael F. Grace, Carolyn M. Bennett, A. Kim Ritchey, Michael R. Jeng, Courtney Thornburg, Michele Lambert, Michelle Neier, Michael Recht, Manjusha Kumar, Victor Blanchette, Robert Klaassen, George R. Buchanan, Margaret A. Heisel Kurth, Diane J. Nugent, Alexis A. Thompson, Kimo Stine, Leslie A. Kalish, Ellis J. Neufeld
Journal: Blood (2010)
Firearm Violence Research
Authors: Ali Rowhani-Rahbar, Morgan A. Bellenger, Frederick P. Rivara
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Very Long-Term Follow-up (&gt; 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients
Authors: Franck E. Nicolini, Marie Balsat, Maud Lekieffre, Vincent Alcazer, Hélène Labussière-wallet, Sarah Huet, Sandrine Hayette, Stéphanie Dulucq, Stéphane Morisset, Jeremy Ruby, Isabelle Tigaud, Marie-Pierre Fort, Mael Heiblig, Rémi Chapelon, Madeleine Etienne, Mohamad Sobh, Francois-Xavier Mahon, Mauricette Michallet, Gabriel Etienne
Journal: Blood (2015)
Plasma Levels of Soluble Interleukin-7 Receptor Alpha (sIL-7Ra) and IL-7Ra Polymorphism After Allogeneic Stemcell Transplantation,
Authors: Zaiba Shamim, Stephanie Thiant, Sylvie Faucher, Bachra Choufi, Lars Ryder, Ibrahim Yakoubagha, Klaus Muller
Journal: Blood (2011)
Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Thromboembolism in Patients after Total Knee Arthroplasty
Authors: Takashi Fuji, Satoru Fujita, Shintaro Tachibana, Yohko Kawai
Journal: Blood (2008)
Evidence for Reduced Angiogenesis in Bone Marrow of Systemic Sclerosis Patients Immunohistochemetry and Computerized Imagine Analysis.
Authors: Valentina Carrai, Renato Alterini, Riccardo Saccardi, Irene Miniati, Luigi Rigacci, Gloria Capaccioli, Irene Donnini, Giada Rotunno, Alberto Bosi, Marco Matucci Cerinic
Journal: Blood (2009)
No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials
Authors: Isabelle Fleury, Sylvie Chevret, Michael Pfreundschuh, Gilles Salles, Bertrand Coiffier, Marinus H.J. van Oers, Christian Gisselbrecht, Emanuele Zucca, Michael Herold, Michele Ghielmini, Catherine Thieblemont
Journal: Blood (2014)
Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
Authors: Shannon L Maude, David M. Barrett, David E Ambrose, Susan R. Rheingold, Richard Aplenc, David T Teachey, Colleen Callahan, Christine S Barker, Maya Mudambi, Pamela A Shaw, Jennifer Brogdon, Regina M Young, John Scholler, Andreas Loew, Katherine T. Marcucci, Jeffrey Finklestein, Irina Kulikovskaya, Farzana Nazimuddin, Zhaohui Zheng, Bruce L. Levine, David L Porter, Simon F. Lacey, Jan J. Melenhorst, Carl H. June, Stephan A. Grupp
Journal: Blood (2015)
Outcome of Adolescent and Young Adults with Acute Myeloid Leukemia Treated with Pediatric Protocols: A Report from the 3 Japanese Cooperative Studies
Authors: Daisuke Tomizawa, Tomoyuki Watanabe, Ryoji Hanada, Keizo Horibe, Yasuo Horikoshi, Shotaro Iwamoto, Akitoshi Kinoshita, Hiroshi Moritake, Hideki Nakayama, Akira Shimada, Takashi Taga, Hiroyuki Takahashi, Akio Tawa, Kiminori Terui, Hiroki Hori, Yoshifumi Kawano, Atsushi Kikuta, Atsushi Manabe, Souichi Adachi
Journal: Blood (2014)
Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis.
Authors: Sergio Cortelazzo, Corrado Tarella, Anna Dodero, Alessandro Massimo Gianni, Zallio Francesco, Manuela Zanni, Alessandro Rambaldi, Tiziano Barbui, Paolo Corradini
Journal: Blood (2004)
Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes
Authors: Christopher Pleyer, Surbhi Sidana, Tomas Radivoyevitch, Remco Molenaar, Andrew Godley, Erik Offerman, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2015)
Expansion of Dysfunctional CD56-Negative NK Cells Is a Hallmark of NK Cell Activation in Ph+ Leukemia Patients Treated with Dasatinib
Authors: Ken-ichi Ishiyama, Toshio Kitawaki, Naoshi Sugimoto, Akifumi Takaori-Kondo, Norimitsu Kadowaki
Journal: Blood (2016)
Cost Comparison of Hematopoietic Stem Cell Transplantation and Conventional Therapy for Patients with Thalassemia Major in China
Authors: Wanxia Tan, Chunfu Li, Xuedong Wu, Yuelin He, Xiaoqin Feng, Jianyun Liao, Huaying Liu, Wenfeng Xu, Yuqiong Ren
Journal: Blood (2015)
Identification of Epigenetically Silenced Tumor Suppressor Genes in Myeloid Disorders Leads to the Identification of α-Catenin as a Target Gene in 5q- Syndrome.
Authors: J. C. Desmond, S. D. Raynaud, L. C. Jones, W. K. Hofmann, T. Haferlach, H. Phillip Koeffler
Journal: Blood (2004)
Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Authors: Thierry Guillaume, Ibrahim Yakoub-Agha, Reza Tabrizi, Cecile Borel, Patrice Chevallier, Leonardo Magro, Stéphane Vigouroux, Pierre Peterlin, Alice Garnier, Marie-Thérèse Rubio, Anne Huynh, Noel Milpied, Philippe Moreau, Mohamad Mohty
Journal: Blood (2016)
The Tet Dioxygenase Co-Factor Ascorbic Acid Reduces DNA Methylation and Increases Expression of the γ-Globin Gene and Acts in a Combinatorial Manner with HbF-Inducing Drugs Targeting Repressive Epigenetic Modifications
Authors: Maria Armila Ruiz, Angela Rivers, Kestis Vaitkus, Vinzon Ibanez, Robert E. Molokie, Joseph DeSimone, Donald Lavelle
Journal: Blood (2014)
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells
Authors: Francesca Chiarini, Cecilia Grimaldi, Francesca Ricci, Pierluigi Tazzari, Ilaria Iacobucci, Giovanni Martinelli, Pasqualepaolo Pagliaro, James McCubrey, Sergio Amadori, Alberto M Martelli
Journal: Blood (2011)
Use of pre-treatment MRI scans to predict toxicity from radiotherapy in patients with Glioblastoma (GB)
Authors: Ramandeep Gill, Samantha Mills, Anthony Chalmers, Cressida Lorimer
Journal: Neuro-Oncology (2019)

Abstract Median life expectancy of patients with Glioblastoma (GB) is 24.4 weeks. Current best treatment involves concurrent use of Temozolomide and radiotherapy. However, toxicity from radiotherapy can limit patient benefit. The objective of this study was to determine the ability of pre-treatment MRI scans of the brain to predict radiotoxicity. This pilot study collected survival and toxicity data from 10 patients aged 65 years or older with a histopathological or radiological diagnosis of GB. Brain MRI scans were used to collect information on tumour characteristics alongside imaging scoring systems to assess medial temporal lobe atrophy, global cortical atrophy and small vessel disease. Scans were analysed by two independent readers. Median survival for this cohort was 35.2 weeks (range 19–59.3 weeks). The beta correlation scores for total contralateral white matter score, global cortical atrophy and T1 contrast volume and survival were all found to equal 1. Beta-correlation coefficients for microanatomical rating score and Schelten’s medial temporal atrophy score were 0.4 and 0.9 respectively. The sum of CTCAE scores for nausea, fatigue and confusion was calculated to provide an overall toxicity score. The mean beta-correlation co-efficient for all scores against toxicity was 1. Use of Bland-Altmann plots showed significant inter-rater reliability for all scores excluding global cortical atrophy. Results from this study suggest a moderate relationship between scan characteristics and increasing toxicity. However, high inter-rater reliability suggests these scoring systems have the potential to be used accurately in clinical practice. A larger study will be conducted to confirm results from this study.
Long-Term Follow-Up of Patients Treated by Gene Therapy for X-Linked Chronic Granulomatous Disease.
Authors: Marion G. Ott, Manuel Grez, Stefan Stein, Ulrich Siler, Ulrike Koehl, Klaus Kuehlcke, Manfred Schmidt, Andrea Schilz, Hana Kunkel, Sonja Naundorf, Andrea Brinkmann, Moustapha Hassan, Christof von Kalle, Adrian Trasher, Reinhard Seger, Dieter Hoelzer
Journal: Blood (2005)
Peripheral Blood Stem Cell (PBSC) Donors Experience Higher Levels of Pain and Toxicities Early On, While Bone Marrow (BM) Donors Experience Slower Recovery and More Late Pain: A Prospective Study of the National Marrow Donor Program (NMDP).
Authors: Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Steven C. Goldstein, John E. Levine, Michael Lankiewicz, David Stroncek, Dennis L. Confer
Journal: Blood (2010)
Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)
Authors: Jose A Garcia-Marco, Javier Lopez-Jimenez, Secundino Ferrer, Pilar Giraldo, Eva González-Barca, Belen Navarro, Eulogio Conde, Marcos González, Jose L. Guzman, Ernesto Perez, Javier De la Serna, Mar Osma, Guillermo Deben, Encarna Monzo, Raquel de Paz, M. Angeles Ruiz, Francisco-Javier Penalver, Isidro Jarque, Helena Bañas, M. Carmen Fernandez, Rafael Martinez, Carmen Burgaleta, Jaime Perez de Oteiza, M.Angeles Andreu, Ana Carral, Inmaculada Fuentes, Eva Donato, Paola Leon, Felix Carbonell, Jose A. Garcia-Vela
Journal: Blood (2010)
A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to An Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity.
Authors: Edmund A Rossi, Eric Chan, Pankaj Gupta, David M. Goldenberg, Chien-Hsing Chang
Journal: Blood (2009)
Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL)
Authors: Massimo Magagnoli, Monica Balzarotti, Antonella Anastasia, Rita Mazza, Laura Giordano, Luca Castagna, Michele Spina, Alessandra Romano, Stefania Bramanti, Armando Santoro
Journal: Blood (2010)
Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia
Authors: Mark B Geyer, Angela M Ricci, Lauren Harrison, Deirdre Duffy, Monica Bhatia, James H Garvin, Diane George, Prakash Satwani, Alexandra C Cheerva, Julie Talano, Fevzi Ozkaynak, Theodore B. Moore, Joseph Schwartz, Lee Ann Baxter-Lowe, Mitchell S. Cairo
Journal: Blood (2010)
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial
Authors: Richard F. Schlenk, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Felicitas Thol, Andrea Kündgen, Thomas Kindler, Hans-Juergen Salwender, Michael Lübbert, Peter Brossart, Jörg Westermann, Doris Kraemer, Katharina Goetze, Heinz-August Horst, Jürgen Krauter, Michael Girschikofsky, Mark Ringhoffer, Thomas Südhoff, Gerhard Held, Hartmut H. Kirchner, Wolff Schmiegel, Richard Greil, Martin Griesshammer, Elisabeth Lange, Uwe Martens, Bernd Hertenstein, Maike de Wit, Elisabeth Koller, Andreas L. Petzer, Tanja Hesse, Volker Runde, Peter Reimer, Beate S. Schultheis, Heinz Kirchen, Frank Griesinger, Holger Hebart, Gerhard Heil, Stephan Kremers, David Nachbaur, Nadezda Basara, Carsten Schwänen, Daniel Schöndube, Jochen Greiner, Anja Münnich, Daniela Weber, Verena I. Gaidzik, Maria-Veronica Teleanu, Peter Paschka, Frauke Theis, Axel Benner, Michael Heuser, Konstanze Döhner, Arnold Ganser, Hartmut Döhner
Journal: Blood (2016)
Survival of patients with melanoma metastatic brain metastases in the era of novel systemic therapies in Cardiff, Wales
Authors: Joseph Pasquale, Joanita Ocen, James Powell, Satish Kumar
Journal: Neuro-Oncology (2019)

Abstract The incidence of malignant melanoma (MM) is increasing in the UK; it’s projected to rise by 7% by 2035. MM has high predisposition to developing brain metastases (BM) with 50–60% of patients being affected. Stereotactic radiosurgery (SRS) and surgery, key interventions in managing patients with BM, have been shown to improve survival outcomes of patients. Patients’ prognosis and survival has also significantly improved with the advent of novel therapies in the last few years. It was noted that the Cardiff Neuro-Oncology multidisciplinary team were receiving increasing amount of referrals for consideration of surgery or SRS in patients with MM. 106 MDT referrals were retrospectively reviewed. 31 patients had surgery, 20 patients had SRS and the remaining 54 patients had WBRT. There was no significant difference in the patient distribution. The majority of patients had 1 brain lesion in both groups (in similar proportions). The 12 month survival for the surgical cohort was 65% for immunotherapy group, 55%- targeted therapy and 30%- no therapy. For the SRS group the 12 month survival for immunotherapy was 45%, targeted therapy- 40% and 20%- no therapy. The median OS for surgery versus SRS was 8 and 7 months respectively. The results suggest that simultaneous treatment with surgery or SRS in conjunction with SACT does improve survival. Interpretation of results will have to be taken with caution due to the retrospective nature and the small sample size. Going forward, we will delve deeper and review local progression rates and SACT timing/sequencing in our practice.
FLT3 Is Involved In Ara-C Transport By Human Equilibrative Nucleoside Transporter (hENT1) In Pediatric Acute Leukemia
Authors: Albert Català, MarÇal Pastor-Anglada, Roberta Malatesta, Susana Rives, Montserrat Torrebadell, Teresa Toll, Ruben Berrueco, Jesús Estella, Mireia Camós, Paula Fernández-Calotti
Journal: Blood (2013)